Product news

Share this article:
Amgen said the European Commission has granted a conditional marketing authorization for Vectibix (panitumumab) as monotherapy for the treatment of patients with epidermal growth factor receptor expressing metastatic colorectal cancer with non-mutated (wild-type) KRAS genes after failure of standard chemotherapy regimens.
Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.